ロード中...
Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy
BACKGROUND: Natalizumab is an effective treatment for relapsing multiple sclerosis. Return of disease activity upon natalizumab discontinuance creates the need for follow-up therapeutic strategies. OBJECTIVE: To assess the efficacy of teriflunomide following natalizumab discontinuance in relapsing m...
保存先:
| 出版年: | Mult Scler J Exp Transl Clin |
|---|---|
| 主要な著者: | , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
SAGE Publications
2019
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6350141/ https://ncbi.nlm.nih.gov/pubmed/30729028 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2055217318824618 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|